Publications

2017

 1.   Population Pharmacokinetics of Piperacillin in Nonobese, Obese and Morbidly Obese Critically Ill Patients

Alobaid AS, Wallis SC, Jarrett P, Starr T, Stuart J, Lassig-Smith M, Mejia JL, Roberts MS, Roger C, Udy AA, Lipman J, Roberts JA.

Antimicrob Agents Chemotherap. 2017 Feb 23;61(3). pii:e01276-16. doi:  10.1128/AAC.01276-16.

2. Antibiotic dosing for multidrug-resistant pathogen pneumonia, Abdul-Aziz, M.H., Lipman, J. and Roberts, J.A. Curr Opin Infect Dis, 2017, 30:231-239 DOI:10.1097/QCO.0000000000000348

 

 

2016

1.  Effects of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients

Alobaid AS, Wallis SC, Jarrett P, Starr T, Stuart J, Lassig-Smith M, Mejia JL, Roberts MS, Roger C, Sinnollareddy MG, Lipman J, Roberts JA.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6550-6557. doi: 10.1128/AAC.01088-16.

2.  Effects of Obesity on the Population Pharmacokinetics on Meropenem in Critically Ill patients

Alobaid AS, Wallis SC, Jarrett P, Starr T, Stuart J, Lassig-Smith M, Ordóñez Mejia JL, Roberts MS, Lipman J, Roberts JA.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4577-84. doi: 10.1128/AAC.00531-16.

3.  Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review

Alobaid AS, Hites M, Lipman J, Taccone FS, Roberts JA.

Int J Antimicrob Agents. 2016 Apr;47(4):259-68. doi: 10.1016/j.ijantimicag.2016.01.009. Epub 2016 Feb 23. Review.

4. Effect of different renal function on antibacterial effect of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling, Bergen, P.J., Bulitta, J.B., Kirkpatrick, C.M.J., Rogers, K.E., McGregor, M.J., Wallis, S.C., Paterson, D.L., Lipman, J., Roberts, J.A. and Landersdorfer, C.B.

J Antimicrob Chemother 2016;71:2509-2520 doi:10.1093/jac/dkw153

 

2015

List of Publications